AstraZeneca PLC Ordinary Shares
AZN · NYSE
- $160.17
- $253.98B
- Open
- —
- —
- $0.00 - $0.00
- $153.41 - $212.71
- —
- —
- 3.09M
- —
- —
- 6.00M
About AstraZeneca PLC Ordinary Shares
AstraZeneca is a global biopharmaceutical company that discovers, develops and sells prescription medicines. Its principal commercial areas include oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, and rare diseases, with vaccines and immune therapies also contributing to the portfolio. It makes money primarily through medicine sales to healthcare systems, hospitals, physicians and patients, supported by regulatory approvals and ongoing clinical development. Oncology is a central franchise, while respiratory and immunology and other specialty-care businesses diversify the portfolio. The supplied evidence provides no current revenue, employee or geographic sales figures, so the company’s present financial scale cannot be quantified here.
Notable Price Movement
- Sep 7-11$160.171.56%
AstraZeneca fell $2.09, or 1.29%, from $162.13 to $160.04 over the observed week. The stock edged up to $162.47 on September 1, slipped to $161.63 the next day, then jumped $3.14 to $164.77 on September 3 before giving back $2.07 on September 4. It fell a further $2.66 on September 8, when volume rose to 5.15 million shares, above the roughly 2.4-3.3 million seen on most earlier sessions. The evidence does not establish which headlines drove individual sessions, but the news flow was mixed: positive survival data for the Amgen-AstraZeneca lung-cancer combination and positive COPD data for tozorakimab contrasted with a reported late-stage oncology trial miss.
- Aug 31 - Sep 4$162.700.00%
AstraZeneca rose $0.25, or 0.15%, from $164.52 to $164.77 over the week, but the path was volatile. The shares fell to $162.13 on Monday after declining from $164.52 on August 27, then edged up Tuesday before slipping to $161.63 on Wednesday. The main company-specific pressure was renewed concern around clinical setbacks, including full data from a failed cardiomyopathy trial that Stocktwits said drove AZN lower. The stock reversed sharply on Thursday, recovering the entire midweek decline, while positive pipeline coverage, including the Tagrisso-plus-Orpathys first-line NSCLC study, supported sentiment. No financial results or explicit weekly guidance change was supplied.
- Aug 24-28$162.701.98%
AstraZeneca fell 1.98% over the week, from $165.98 to $162.70. The stock initially gained, rising to $166.71 on Monday and $169.66 on Tuesday, before reversing sharply: it dropped to $166.27 on Wednesday, $164.52 on Thursday and $162.70 on Friday. The principal company-specific development was positive Phase 3 CROSSING data for Tezspire, the AstraZeneca-Amgen treatment for eosinophilic esophagitis, which met its co-primary and key secondary endpoints. That news did not prevent the subsequent three-day decline. The supplied evidence does not identify a negative AstraZeneca announcement or guidance change, so the late-week selling appears to have occurred without a clearly documented company-specific catalyst; broader market context is limited to a report of U.K. stocks closing 0.33% higher.
- Aug 10-14$156.453.08%
AstraZeneca rose $3.94, or 2.49%, from $157.97 to $161.91 across the supplied closes. Trading was volatile rather than steadily higher: the stock fell $2.35 on August 4 before surging $5.88 on August 5, then held near $161 through August 7 and added $0.49 on August 10. The clearest company-specific references in the supplied coverage were an earnings beat and reports that AstraZeneca ended takeover discussions with Bristol Myers Squibb after its share price dropped, although neither item is dated sufficiently to establish a direct causal link to each session. With no broader-market performance or other dated catalyst supplied, the week is best described as a rebound and consolidation without a fully explained company-specific driver.
- Aug 3-7$161.424.85%
AstraZeneca fell 9.78% over the week, from $172.48 to $155.62. The decline was concentrated on Monday, when the stock dropped to $157.97 on volume of 16.3 million shares, followed by a further fall to $155.62 on Tuesday. The main reported catalyst was news that AstraZeneca and Bristol Myers Squibb were in talks over a potential $400 billion combination, which appears to have heightened concerns about regulatory scrutiny and integration risks. The stock did not materially reverse the Monday selloff. No company financials were supplied for the period, so the move is best attributed to deal-related uncertainty rather than an earnings update.
